Immunoreactive serum erythropoietin (EPO) was measured in anemic and non-anemic patients with acquired non-severe aplastic anemia (AA; n = 22) and myelodysplastic syndromes (MDS; n = 31) receiving or not androgens to examine the effect of androgen therapy and anemia on EPO levels in these disorders.
Flowcytometric detection of PNH defect in Indian patients with aplastic anemia and myelodysplastic syndromes
β Scribed by Neelam Varma; Gurjeevan Garewal; Subhash Varma; Harpreet Vohra
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 156 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
This study was designed to evaluate the utility of blasts with a clear halo around their nucleoli (BCHN) as a predictive indicator of disease progression in myelodysplastic syndromes (MDSs) and aplastic anemia (AA). Bone marrow aspirates from 75 patients with MDSs and 18 with AA were fixed in 95% et
Previously, we reported that patients with aplastic anemia (AA) have profoundly decreased numbers of hematopoietic progenitor and stem cells as measured in the longterm culture initiating cell (LTC-IC) assay (Blood 1996;88:1983-1991). We now present results of a long-term prospective study of LTC-IC